Edwards Lifesciences traded down 0.56% on Wednesday, hitting $85.76. Edwards Lifesciences has a 1-year low of $61.59 and a 1-year high of $91.50. The company has a market cap of $9.777 billion and a price-to-earnings ratio of 43.14.
Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of Edwards Lifesciences from $90.00 to $97.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday. Finally, analysts at GARP Research reiterated a “buy” rating on shares of Edwards Lifesciences in a research note to investors on Monday.
Edwards Lifesciences Corporation (Edwards Lifesciences) is a global player in products and technologies designed to treat advanced cardiovascular disease.